CN109793753A - A kind of Derma-Guard of antibiotic skin-care - Google Patents
A kind of Derma-Guard of antibiotic skin-care Download PDFInfo
- Publication number
- CN109793753A CN109793753A CN201711143769.9A CN201711143769A CN109793753A CN 109793753 A CN109793753 A CN 109793753A CN 201711143769 A CN201711143769 A CN 201711143769A CN 109793753 A CN109793753 A CN 109793753A
- Authority
- CN
- China
- Prior art keywords
- derma
- skin
- calcium
- guard
- guard according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of Derma-Guard of antibiotic skin-care of the present invention; it is aminoglycan to combine manufactured biological agent in the liquid medium containing catalyst pH2.7 to pH5.3 by weight percentage with sterol and terpenoid substance, as the antibiotic skin-care Derma-Guard for being applied to treatment skin eczema, pruitus and skin infection and protection skin wound and moistening skin beautifying.
Description
Technical field
The present invention relates to biomedicine fields, specifically, be biological agent preparation and its treatment skin disease on
Application.
Background technique
Skin is the largest organ for protecting human body, is the important barrier of human health, is risen to the health of maintenance human body body
Highly important effect.It is easiest to cause skin disease when the physiological function of skin is damaged, hurt as caused by physical factor
Mouth and high temperature are scalded, allergic reaction or microorganism infection caused by biological factor, allergy caused by food or neural sexual factor etc.,
The most common skin disease is pruitus, dermatitis and skin infection.Skin disease to people's lives and work influence very
Seriously.
The current most common dermatitis is eczema, this be a kind of cause of disease it is extremely complex with related disease is immunized.It is main at present
It will be using external application glucocorticoid creme (such as hydrochloric acid dexamethasone, hydrocortisone etc.) and antibiotics etc., in cooperation
The drug of clothes such as antihistamine drug (fluorine Lei Tading, cetirizine), neuroleptic agent and antibiotic etc., these external applications and endo-medicine
All being also easy to produce drug resistance in the presence of long-time service leads to skin disease recurrent exerbation, and is easy to influence people due to the toxic side effect of drug
Body health.Up to now, clinically still lack safe and effective and economical and practical eczema drug.
Skin infection is mainly caused by microorganism infection, such as tinea pedis is exactly to be caused by fungal infection.Treating initial infection is first
It is raw in single human hair combing waste, but it can be transmitted to an other foot quickly.The skin lesion of tinea pedis has a feature, i.e. clear border, can be gradually
It extends to the outside.Usually because of progression of the disease or scratching, it may occur in which rotten to the corn, sepage or even bacterium infection, warts etc. occur.Infect foot
The fungi of tinea is since long-time is in moist environment, and fungi invades skin surface, and antifungal medicine is not easy to penetrate into, it is often necessary to
Antifungal is used again after making cutin softening using salicylic acid or benzoic acid etc., and damage of these medicaments to skin is big, and skin resists
Bacterium property can also be destroyed simultaneously, and symptom is caused more to deteriorate.
Pruitus be only itch but without primary cutaneous damage dermatological conditions.According to the range of pruitus and
Position is generally divided into systemic and locality two major classes.Systemic itch may with certain diseases occur together or onset symptoms have
It closes, is then more related with environmental factor, external drug, the especially factors such as dry skin.Locality itch can occur
At any position of body, occur mainly as chemical mediator as caused by the release of histamine, kassinin kinin and protease etc..Skin
Antihistamine and corticoid are commonly used in the treatment of itch, same to make for a long time because its toxic side effect influences human health
With.
It is main using for oral administration and Topical therapy at present as described above for the above skin disease, be substantially all be related to using
Steroids and antibiotics medicament, it is unhealthful that long-time service is easy to produce toxic side effect, and drug resistance is caused to generate, and makes skin
Skin disease recurrent exerbation, it more difficult to treat, usually such as pruitus and eczema occur these skin diseases for interaction.So developing a kind of effect
Fruit is significantly and the drug of broad-spectrum curing skin disease, protection skin health has very important significance.
Summary of the invention
The endpoint of disclosed range and any value are not limited to the accurate range or value herein, these ranges or
Value should be understood as comprising the value close to these ranges or value.For numberical range, between the endpoint value of each range, respectively
It can be combined with each other between the endpoint value of a range and individual point value, and individually between point value and obtain one or more
New numberical range, these numberical ranges should be considered as specific open herein.
For overcome the deficiencies in the prior art, after the present invention combines aminoglycan with terpenes and sterol by weight percentage
Biological agent made of being combined under conditions of pH2.7 to pH5.3 under the action of catalyst, as applied to treatment skin disease
Disease protects the combination preparation of skin wound and moistening skin beautifying.
The aminoglycan of selection is to constitute the base of these glycan by the polysaccharide being polymerize by 2-7000 monosaccharide containing amino
Plinth molecular formula is the monosaccharide of 6 carbon atoms, can come from plant, animal or microorganism, including but not limited to: glycosaminoglycan,
Amino-oligosacchride, chitosan, glycosaminoglycan, chitosan, astragalus polyose, panaxan, notoginseng polysaccharide, dictyophora fungus polysaccharide, ganoderma lucidum are more
At least one of sugar and zymosan.Most preferably, the aminoglycan is amino-oligosacchride.
The sterols of selection can be the sojasterol extracted from animals and plants or microorganism, avenasterol, ergosterol
At least one of.Most preferably, the sterol is ergosterol.
The terpenes of selection can be the single times of terpene extracted from animals and plants or microorganism or more times of terpene such as laurenes, lemon
Lemon alkene, tea polyphenols, hundred fragrant phenol, Melaleuca oil, at least one of menthol.Most preferably, the terpenes is cajeputtree essence
Oil.
In the present invention, the catalyst includes inorganic compound or biocatalyst, it is preferable that including but not limited to,
Calcium chloride, sodium chloride, potassium chloride, zinc oxide, calcium oxide, calcium superphosphate, sodium tripolyphosphate, sodium bicarbonate, sodium polyphosphate, di(2-ethylhexyl)phosphate
Hydrogen potassium, dipotassium hydrogen phosphate, disodium-hydrogen, sodium sulphate, zinc sulfate, copper sulphate, zinc acetate, potassium sulfate, calcium carbonate, amino acid
Calcium, amino-acid zinc, glucan calcium, glucan zinc, sodium carbonate, calcium bicarbonate, saleratus, calcium sulfate, calcium nitrate, glucose
In calcium, potassium carbonate, Bacillus acidi lactici, bacillus, Lactococcus, Bacillus acidi lactici, saccharomycete, biological enzyme and pseudomonad at least
It is a kind of.The more preferably biocatalyst of Bacillus acidi lactici and saccharomycetes to make fermentation liquid.
The material of above-mentioned material composition used can be commercially.
Derma-Guard provided by the invention is that the pH in the liquid containing catalyst is with sterol and terpenes by aminoglycan
It combines and is made under conditions of 2.7-5.3.
The present invention also provides above-mentioned Derma-Guards in treatment skin disease and protection skin wound and moisturizing beauty
Application in appearance.
In the present invention, the skin disease addressed includes the acute and chronic eczema occurred in body different parts, caused by eczema
Itch, nerve and spirituality itch, itch caused by external drug, alkaline soap and dry skin etc., and occur in body
Infection caused by the fungi and bacterium of different parts, such as ringworm of the body and tinea pedis.
Present invention solves the technical problem that being the fermentation liquid of aminoglycan and sterol and terpenes in Bacillus acidi lactici and saccharomycete
In combination preparation obtained.This preparation can be used for treating skin disease, protect the effect of skin wound and moistening skin beautifying.
Innovative point of the invention is will be containing the polysaccharide and a kind of or polyterpene that the monosaccharide of the 2-7000 of amino polymerize in cream
There is the combination preparation of synergistic function, this preparation can be used for treating made of in the fermentation liquid of acidfast bacilli and saccharomycete
Skin disease protects the effect of skin wound and moistening skin beautifying.
Specific embodiment
The present invention is further described according to following examples, one skilled in the art will appreciate that following embodiments to the present invention only
Only play the role of explanation.Without departing from the premise in the spirit of the present invention, exist to any improvement of the invention done and substitution
In the scope of protection of the invention.
Embodiment 1
Fermentation liquid preparation: saccharomycete is cultivated 48 hours at MEB culture medium, 28 DEG C, cell concentration reaches 5.1 x 109
cfu/ml。
Bacillus acidi lactici is cultivated 48 hours at 28 DEG C of LB culture medium, cell concentration reaches 3.6 x 1010cfu/ml.It will
Saccharomycetes to make fermentation liquid is mixed with lactobacillus fermentation liquid by 2:1, shakes up and 1000 milliliters of mixed fermentation liquids are made, and amino-oligosacchride is added
It 6 grams, 8 grams and 12 grams of cajeputtree of ergosterol, is sufficiently mixed uniformly, aminoglycan skin sparing combination preparation is made.
Embodiment 2
10 uniform albino guinea-pigs of hair removal section burn surface area are divided into 2 groups, every group 5, first group every with traditional ointment for treating burn
It smear 2 times as a comparison, second group smear 2 times, 1 week daily with aminoglycan Derma-Guard of the invention after observe effect
Fruit.
Aminoglycan Derma-Guard of the invention can rapidly promote the healing of cavy wound, and the scar left is not
Obviously.
Embodiment 3
The tinea pedis patient of 16 bipeds in spite of illness is selected, every patient fixes a foot and aminoglycan Derma-Guard is used to smear trouble daily
Place, another are not applied with comparing enough, are observed after 7 days, and the affected part tinea class for smearing aminoglycan Derma-Guard falls off, gradually extensive
It is multiple normal.
Claims (12)
1. a kind of Derma-Guard of antibiotic skin-care, which is characterized in that the Derma-Guard is by aminoglycan and sterols and terpene
Alkenes substances in percentage by weight combines manufactured biological agent in the liquid medium containing catalyst pH2.7 to pH5.3, makees
For applied to treatment skin eczema, pruitus and skin infection and the biological agent for protecting skin wound and moistening skin beautifying.
2. Derma-Guard according to claim 1, wherein the aminoglycan is by a by 2-7000 containing amino
Monosaccharide polymerization polysaccharide, constitute these glycan base molecule formula be 6 carbon atoms monosaccharide, can come from plant, animal or
Microorganism, including but not limited to: glycosaminoglycan, amino-oligosacchride, chitosan, glycosaminoglycan, chitosan, astragalus polyose, people
Gracilis polysaccharide, notoginseng polysaccharide, dictyophora fungus polysaccharide, at least one of ganoderma lucidum polysaccharide and zymosan.
3. more preferably amino-oligosacchride.
4. Derma-Guard according to claim 1, wherein selected sterols, including but not limited to: driven plant
The sojasterol extracted in object or microorganism, avenasterol, at least one of ergosterol.
5. more preferably ergosterol.
6. Derma-Guard according to claim 1, wherein selected terpenes, including but not limited to: driven plant
The single times of terpene or more times of terpene such as laurenes extracted in object or microorganism, limonene, tea polyphenols, hundred fragrant phenol, Melaleuca oil, peppermint
At least one of alcohol.
7. Derma-Guard according to claim 1, wherein the aminoglycan and sterols and terpenes weight percent
Aminoglycan 5-25: sterol 8-15: terpenes 5-20 is combined into than group.
8. Derma-Guard according to claim 1, wherein the catalyst includes but is not limited to: inorganic compound
And/or biocatalyst.
9. Derma-Guard according to claim 1, wherein the skin eczema and pruitus include but do not limit to
In: the itch caused by the acute and chronic eczema and eczema of body different parts, nerve and spirituality itch, externally applied drug occurs
Itch caused by object, alkaline soap and dry skin etc..
10. Derma-Guard according to claim 1, wherein the skin infection includes but is not limited to: occurring in body
Infection caused by the fungi and bacterium of body different parts, such as ringworm of the body and tinea pedis.
11. Derma-Guard according to claim 5, wherein the catalyst includes but is not limited to calcium chloride, chlorination
Sodium, potassium chloride, zinc oxide, calcium oxide, calcium superphosphate, sodium tripolyphosphate, sodium bicarbonate, sodium polyphosphate, potassium dihydrogen phosphate, phosphoric acid hydrogen
Dipotassium, disodium-hydrogen, sodium sulphate, zinc sulfate, copper sulphate, zinc acetate, potassium sulfate, calcium carbonate, amino acid calcium, amino-acid zinc,
Glucan calcium, glucan zinc, sodium carbonate, calcium bicarbonate, saleratus, calcium sulfate, calcium nitrate, calisanin, potassium carbonate, lactic acid
At least one of bacillus, bacillus, Lactococcus, leukonid, saccharomycete, biological enzyme and pseudomonad.
12. more preferably Bacillus acidi lactici and saccharomycetes to make fermentation liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711143769.9A CN109793753A (en) | 2017-11-17 | 2017-11-17 | A kind of Derma-Guard of antibiotic skin-care |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711143769.9A CN109793753A (en) | 2017-11-17 | 2017-11-17 | A kind of Derma-Guard of antibiotic skin-care |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109793753A true CN109793753A (en) | 2019-05-24 |
Family
ID=66554835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711143769.9A Pending CN109793753A (en) | 2017-11-17 | 2017-11-17 | A kind of Derma-Guard of antibiotic skin-care |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109793753A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102453679A (en) * | 2010-10-26 | 2012-05-16 | 冯坤范 | Zymotic fluid for biofermentation and preparation method thereof |
| CN104784199A (en) * | 2014-01-20 | 2015-07-22 | 黄永 | Glycan composition for activating immunity to treat pathogen infection |
| CN105496938A (en) * | 2015-12-29 | 2016-04-20 | 苏州工业园区安诺科斯化妆品研发有限公司 | Alpha-bisabolol skin lotion |
| US20160120792A1 (en) * | 2013-05-10 | 2016-05-05 | Freelife International, Inc. | Formulations and methods for improving skin conditions |
| CN105596275A (en) * | 2016-01-06 | 2016-05-25 | 名臣健康用品股份有限公司 | Cosmetic substrate containing double-bacterium fermentation soy milk extract and application |
| MX2015008246A (en) * | 2015-06-24 | 2016-12-23 | Francisco Gamboa Guillermo Ricardo | Topical composition with ionic silver for the treatment of infected skin wounds. |
| CN106963977A (en) * | 2017-05-26 | 2017-07-21 | 广东海洋大学 | A kind of Breviscapinun/chitosan composite aquogel for suppressing cicatrization and preparation method thereof |
-
2017
- 2017-11-17 CN CN201711143769.9A patent/CN109793753A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102453679A (en) * | 2010-10-26 | 2012-05-16 | 冯坤范 | Zymotic fluid for biofermentation and preparation method thereof |
| US20160120792A1 (en) * | 2013-05-10 | 2016-05-05 | Freelife International, Inc. | Formulations and methods for improving skin conditions |
| CN104784199A (en) * | 2014-01-20 | 2015-07-22 | 黄永 | Glycan composition for activating immunity to treat pathogen infection |
| MX2015008246A (en) * | 2015-06-24 | 2016-12-23 | Francisco Gamboa Guillermo Ricardo | Topical composition with ionic silver for the treatment of infected skin wounds. |
| CN105496938A (en) * | 2015-12-29 | 2016-04-20 | 苏州工业园区安诺科斯化妆品研发有限公司 | Alpha-bisabolol skin lotion |
| CN105596275A (en) * | 2016-01-06 | 2016-05-25 | 名臣健康用品股份有限公司 | Cosmetic substrate containing double-bacterium fermentation soy milk extract and application |
| CN106963977A (en) * | 2017-05-26 | 2017-07-21 | 广东海洋大学 | A kind of Breviscapinun/chitosan composite aquogel for suppressing cicatrization and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| GASPAR L.R. ET AL: "Evaluation of dermatological effects of cosmetic formulations containing", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
| 冯延民: "《壳寡糖与人类健康》", 31 March 2008, 吉林大学出版社 * |
| 王茜 等: "皮肤微生态与化妆品研发", 《日用化学工业》 * |
| 田日新: "《做女人的营养师：女人营养一本通》", 31 May 2017, 陕西科学技术出版社 * |
| 袁昌齐 等: "《世界植物药》", 31 January 2013, 东南大学出版社 * |
| 马玉华 等: "《火龙果高效栽培技术》", 30 April 2017, 贵州科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3223833B1 (en) | Prevention and treatment of microbial infections | |
| KR102132544B1 (en) | Petrolatum-based delivery system for active ingredients | |
| Alam et al. | Honey: a potential therapeutic agent for managing diabetic wounds | |
| EP3875100A1 (en) | Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation | |
| US20110091572A1 (en) | Acne treatment compositions comprising nanosilver and uses | |
| EP2575971B1 (en) | Combined plant extracts for use in the treatment of microbial infections | |
| WO2008140200A1 (en) | External compositions for the skin | |
| CN105431154A (en) | Anti-microbial composition | |
| Alalor et al. | Evaluation of the antibacterial activity of herbal ointments formulated with methanolic extract of Cassia alata | |
| CN104622751A (en) | Traditional Chinese medicine biogel for treating pimples | |
| US20210244785A1 (en) | Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue | |
| CN111317675B (en) | Acne removing composition containing D-panthenol, application of acne removing composition and cosmetics containing composition | |
| CN104474536A (en) | Fresh agrimonia pilosa medicine preparation for treating wounds | |
| CN109793753A (en) | A kind of Derma-Guard of antibiotic skin-care | |
| CN115721706A (en) | Composition for treating eczema dermatitis and preparation method and application thereof | |
| US8486459B2 (en) | Bulbine frutescens extract | |
| US20240108697A1 (en) | Antimicrobial compositions | |
| AU2007298511B2 (en) | Compositions for prevention and treatment of mastitis and metritis | |
| Lavanya et al. | Aloe vera on skin. | |
| CN113842405B (en) | Application of broussonetia papyrifera root-bark extract in preparation of anti-allergic and itching-relieving medicine for skin | |
| Belkacem et al. | Antihyperglycaemic effect of hydroalcoholic extract from Punica granatum L. peels in normal and streptozotocin-induced diabetic rats and its potent α-amylase inhibitory | |
| CN112370464A (en) | Marine oligosaccharide composition for treating beriberi | |
| KR20170043199A (en) | Natural Antiseptic Composition Containing Garlic and Ciboule Root Extracts | |
| CN104623035A (en) | Pharmaceutical composition for treating acnes | |
| CN113116984A (en) | Herbal formula for treating beriberi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.1, 1st floor, building 6, No.2 Tianyu Road, Chengdu high tech Zone, Chengdu, Sichuan 610041 Applicant after: Chengdu Auli Ecological Technology Development Co.,Ltd. Address before: No. 5 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Applicant before: Chengdu Auli Ecological Technology Development Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190524 |
|
| WD01 | Invention patent application deemed withdrawn after publication |